BDA
AZN icon

Borer Denton & Associates’s AstraZeneca AZN Stock Holding History

Borer Denton & Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$315K Buy
1,627
+77
+5% +$14.8K 0.11% 61
2025
Q4 		$285K Buy
+1,550
New +$272K 0.1% 60

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Borer Denton & Associates's AZN Position: Q1 2026 in Review

Borer Denton & Associates increased its AstraZeneca (AZN) stake by 5% in Q1 2026, buying an estimated $14.8K and bringing the position to 1,627 shares worth $315K. The position accounts for 0.11% of the portfolio, ranked #61.

Borer Denton & Associates first reported a position in AZN in Q4 2025 and has held it in 2 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Borer Denton & Associates held 1,627 shares of AstraZeneca worth $315K as of Q1 2026.
  • Borer Denton & Associates bought 77 AstraZeneca shares in Q1 2026, an estimated $14.8K.
  • AstraZeneca made up 0.11% of Borer Denton & Associates's portfolio in Q1 2026, its #61 holding.
  • Borer Denton & Associates first reported a position in AstraZeneca in Q4 2025 and has held it in 2 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Borer Denton & Associates's 13F filing for Q1 2026, filed 12 May 2026.